Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that the Company has entered into a distribution and supply agreement with a leading Indonesian pharmaceutical companies PT. Erlangga Edi Laboratories (“PT. Erela”), for commercializing CsA Ophthalmic Gel, a self-developed innovative treatment for moderate-to-severe dry eye disease (“DED”), in Indonesia domestically.

Under the terms of the agreement, Zhaoke grants PT. Erela exclusive rights to register, import, promote, distribute, market, and sell CsA Ophthalmic Gel in Indonesia. The Company will receive an upfront payment and is eligible to receive additional milestone payments based on specific achievements.

In May 2024, Zhaoke signed a Memorandum of Understanding (“MoU”) with PT. Erela during the Asia Summit on Global Health (“ASGH”), which was organized by the Hong Kong Trade and Development Council (“HKTDC”) and has long been a premier platform for global healthcare exchange and collaboration. While the MoU served as an exploratory framework, it ultimately paved the way for the strategic partnership established today.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “We are excited to announce our partnership with PT. Erela to promote the commercialization of our CsA Ophthalmic Gel therapy for moderate to severe DED. This partnership is Zhaoke’s third strategic collaboration in Indonesia, and our second for DED. We now have partnerships secured for myopia, presbyopia and DED across what is one of Asia’s largest markets.”

About CsA Ophthalmic Gel

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to severe DED. Unlike Restasis®, an emulsion formulation, Cyclosporine ophthalmic gel is a patented hydrogel featuring excellent mucoadhesion and prolonged corneal residence time. Adopting nanomicelle formulation technology, it enhances corneal penetration and boosts the bioavailability of cyclosporine A.

Previous phase II study results suggested that 0.05% CsA Ophthalmic Gel (q.d.), applied once daily at night, had efficacy and safety profiles at least similar to those of Restasis® (0.05% CsA, b.i.d.) which is applied twice daily. This effectively eliminates the need for daytime administration and the associated discomfort and inconvenience. In addition, the results of the previous phase III study (COSMO) conducted by the Company indicate that the onset of action for CsA Ophthalmic Gel can start in as early as two weeks. As a result of once daily application and a rapid onset of action, the Company expects its CsA Ophthalmic Gel to significantly improve patients’ compliance and quality of life.

About PT. Erlangga Edi Laboratories (“PT. Erela”)

PT Erela is a leading Indonesian pharmaceutical company established in 1965 by Drs. Edi Handojo and Dra. Kusumawati Handojo. The company began its operations on Jalan Erlangga in Semarang, Indonesia, and has since evolved into a trusted manufacturer with a strong legacy in quality, accessibility, and pharmaceutical innovation. Since 1996, Dra. Lily Radite Handojo, the founders’ youngest daughter, has led the company’s continued growth and transformation into a modern pharmaceutical enterprise.

Today, PT Erela is engaged in the development and manufacturing of pharmaceuticals, traditional medicines, health supplements, and health beverages, with a diversified portfolio of more than 150 SKUs. The company serves both domestic and international market needs, supported by robust manufacturing capabilities and a commitment to high-quality, affordable healthcare products.

PT Erela operates two manufacturing facilities located in Semarang and Salatiga, Indonesia. Across these facilities, the company produces more than 10 dosage forms, with an oral solid dosage production capacity exceeding 3.5 billion tablets and an eye drop production capacity of more than 30 million bottles annually. PT Erela is certified by Indonesia’s National Agency of Drug and Food Control (BPOM) and operates in compliance with PIC/S GMP standards. The company also holds ISO and Halal certifications, and continues to advance its operational excellence through Industry 4.0 initiatives.

With an extensive commercial and distribution network, PT Erela reaches more than 10,000 pharmacy outlets and major hospital chains across Indonesia. This broad market access, combined with strong manufacturing and regulatory capabilities, positions the company as a reliable partner for pharmaceutical companies seeking to expand their presence in Indonesia and the broader regional market.

In addition to its proprietary product portfolio, PT Erela provides professional toll manufacturing services for pharmaceutical enterprises. Leveraging its technical expertise, scalable production capacity, and regulatory compliance capabilities, the company offers comprehensive manufacturing support and strategic partnership opportunities for industry players across the pharmaceutical sector. For more information, please visit www.erela.co.id.

- End -